Clinical Trials

Clinical trials are the final step in a long process of research. They allow scientists to test the value of their research to diagnose, treat and prevent diseases and disabilities. 

Each clinical trial is an opportunity to test a promising new invention or treatment in humans for the first time.

Clinical trials for people with pituitary disorders include:

Recruiting participants

Study:Trial to Compare the Efficacy and Safety of NNC0195-0092 With Placebo and Norditropin® FlexPro® in Adults With Growth Hormone Deficiency (REAL 1)
Condition: Adult Growth Hormone Deficiency
Intervention: Drug: NNC0195-0092, Drug: somatropin, Drug: placebo

Study: Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: LCI699

Study: A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency
Condition: Adult Growth Hormone Deficiency
Intervention: Drug: MOD-4023

Study: Treatment for Endogenous Cushing's Syndrome
Condition: Endogenous Cushing's Syndrome
Intervention: Drug: COR-003


Not yet recruiting

Study: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (MPOWERED)
Condition: Acromegaly
Intervention: Drug: Octreotide capsules, Drug: Injectable Somatostatin Analogs (octreotide or lanreotide), Drug: Cabergoline

Completed (Dr. Fleseriu was the principal investigator at OHSU)

  1. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
  2. Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)
  3. Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
  4. Safety and Efficacy of LCI699 in Cushing's Disease Patients
  5. Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study (SODA)
  6. An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)
  7. A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
  8. A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (SEISMIC)
  9. An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
  10. Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
  11. Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Participating in Clinical Trials at the OHSU Northwest Pituitary Center

If you are interested in participating in a clinical trial, you can find more information by calling the Neurological Surgery Clinical Trials Coordinator at 503 494-9546

About Clinical Trials at OHSU

Oregon Health & Science University requires all investigators that are conducting human subjects' research to respect and protect the rights and welfare of participants recruited for, and/or participating in, research under the supervision of OHSU. As part of this commitment, Responsible Conduct of Research education is required of all investigators, research staff, and other relevant personnel.

All clinical research undertaken at OHSU is subject to approval by the institutional review board (IRB).
The institutional review board is a group that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans with the aim of protecting the rights and welfare of the subjects. The IRB approves, requires modifications to, or disapproves clinical research. The IRB performs critical oversight functions for research conducted on human subjects that are scientific, ethical, and regulatory.

OHSU Research Integrity Office

For more information about clinical trials and a nationwide database of clinical trials, please go to the U.S. National Institutes of Health clinical trials web site.